BTK and B-cell chronic lymphocytic leukemia: Fludarabine and cyclophosphamide can downregulate IDO expression in malignant B-cells [58], but there are not data about the off-target effects on mo-MDSCs of Bruton tyrosine kinase (BTK) inhibitors currently used in clinical management of CLL patients.